Bharat Biotech’s Covaxin shows long-term antibodies

Vastavam web: Ever since the outbreak of coronavirus, scientists knew there was a need for a vaccine to prevent the viral infection from spreading. After working tirelessly for months, scientists have successfully produced vaccines to counter the effects of SARS-CoV-2. As the world gears up against COVID-19, India has emerged one of the successful countries to have discovered a vaccine.

Covaxin, India’s indigenous COVID-19 vaccine by Bharat Biotech, is developed in collaboration with the Indian Council of Medical Research and the National Institute of Virology (NIV). A new study suggests that Covaxin showed long-term antibody and T-cell (immune) memory responses three months after the shot on phase 1 volunteers and tolerable safety outcomes in Phase 2 study. In phase 2, it also showed an enhanced humoral, and cell-mediated immune response and the results were found in the safety and immunogenicity clinical trial of the vaccine candidate.

In a double-blind, randomized, multi-centre phase 2 clinical trials, a total of 380 healthy children and adults were randomized and administered two vaccine formulations in as many doses, four weeks apart. Covaxin produced high levels of neutralizing antibodies that remained elevated in all participants three months after the second vaccination.
Based on these results, researchers hypothesize that BBV152 (Covaxin) can generate antibodies that may protect people for at least 6-12 months.